Physician profile
Lindsey E Link
NPI 1487107330
$3,361.32
in general payments reported to CMS, 2019-2025
26 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,135 · 2022: $877 · 2023: $425 · 2024: $552 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,349.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $583.15 | 2021-2025 | |
| Novo Nordisk INC | $533.15 | 2021-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $357.92 | 2021-2025 | |
| Lilly USA, LLC | $341.94 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $321.11 | 2021-2024 | Otezla, Repatha |
| Amarin Pharma, INC. | $228.00 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $124.87 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.09 | 2021-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $77.93 | 2021-2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $74.72 | 2021-2024 | Veozah |
| Merck Sharp & Dohme LLC | $70.33 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Biohaven Pharmaceutical Holding Company LTD. | $66.09 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $60.52 | 2024-2025 | Airsupra |
| Janssen Pharmaceuticals, INC | $60.14 | 2021-2022 | |
| Boston Scientific Corporation | $54.79 | 2024-2025 | Watchman Flx |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $47.02 | 2024-2025 | Cologuard Collection Kit |
| Genzyme Corporation | $43.63 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.46 | 2021 | |
| Gilead Sciences, INC. | $34.76 | 2022 | |
| Sanofi Pasteur INC. | $27.23 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.53 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $18.27 | 2022 | |
| Ardelyx, INC. | $14.87 | 2025 | Ibsrela |
| Paratek Pharmaceuticals, INC. | $14.09 | 2024 | Nuzyra |
| Hologic Sales and Service, LLC | $13.37 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Link listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.